<DOC>
	<DOCNO>NCT00004567</DOCNO>
	<brief_summary>This study compare safety effectiveness two drugs-methotrexate mycophenolate mofetil ( MPM ) -in prevent disease recurrence patient Wegener 's granulomatosis relate inflammatory blood vessel disorder . The standard treatment condition combination drug therapy prednisone plus cyclophosphamide . However , although patient improve therapy achieve disease remission , many experience relapse ( return disease ) time therapy stop . Also , drug produce serious side effect treatment . This study test new treatment regimen try maintain disease remission patient minimal side effect . Patients Wegener 's granulomatosis relate blood vessel disorder 10 80 year old consider study . All participant start therapy daily dos prednisone cyclophosphamide . Prednisone reduce gradually stop symptom improve significantly . Cyclophosphamide continue disease remission . Patients remission randomly assign continue treatment either MPM methotrexate . MPM take twice day mouth . Methotrexate take week , usually mouth , case , injection muscle skin . Patients well side effect continue treatment 2 year . Then , drug gradually reduce ( usually monthly interval ) finally stop . No treatment give unless relapse occurs . At time , type treatment depend various medical factor , include severity recurrence patient 's history drug side effect . Physical examination various test , include blood urine analysis , X-rays , do periodically evaluate response treatment monitor drug side effect . The total duration study-from screen evaluation 2-year follow medication stopped-is 5 6 year .</brief_summary>
	<brief_title>Comparison Treatments Maintain Disease Remission Patients With Wegener 's Granulomatosis Related Vasculitis Syndromes</brief_title>
	<detailed_description>The purpose study assess comparative efficacy use methotrexate versus mycophenolate mofetil maintain remission induce cyclophosphamide glucocorticoid patient Wegener 's granulomatosis relate vasculitides . In study , patient initially receive daily cyclophosphamide glucocorticoid disease remission , cyclophosphamide discontinue patient randomize receive either methotrexate mycophenolate mofetil remission maintenance . They continue receive agent randomize 2 year , time taper discontinue . Patients prospectively monitor evidence disease relapse drug toxicity . Specific parameter obtain include time disease remission , rate time disease relapse , incidence drug-related adverse event .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Documentation Wegener 's granulomatosis ( WG ) relate systemic vasculitis base clinical characteristic histopathologic and/or angiographic evidence vasculitis . In absence histopathologic and/or angiographic evidence vasculitis , patient meet one follow criterion infectious autoimmune disease may mimic WG related systemic vasculitides exclude also eligible : A . A positive assay antineutrophil cytoplasmic autoantibody ( C PANCA ) presence glomerulonephritis define red blood cell cast proteinuria renal biopsy show necrotizing glomerulonephritis absence immune deposit . B . A positive assay antineutrophil cytoplasmic autoantibody ( C PANCA ) presence granulomatous inflammation biopsy plus abnormal chest radiograph ( define presence nodule , fix infiltrates , cavity ) plus nasal/oral inflammation clinical examination . 2 . Age 1080 year . 3 . Evidence active disease define Vasculitis Disease Activity Index great equal 3 begin CYC glucocorticoid outside institution , history Vasculitis Disease Activity Index great equal 3 time therapy initiation . EXCLUSION CRITERIA : 1 . Evidence active infection , judgment investigator , great danger patient underlie vasculitis . In instance infection rule gram stain culture secretion collection fluid involved organ , may necessary obtain biopsy affected tissue microbiological histopathological study . 2 . Patients pregnant nursing infant eligible . Fertile woman must negative pregnancy test within one week prior study entry must use effective mean birth control . 3 . Serological evidence infection human immunodeficiency virus , hepatitis C , positive hepatitis B surface antigen . A serological determination perform within two week begin study participation . 4 . Acute chronic liver disease , past history alcohol abuse ( great 14 oz 100 proof liquor equivalent per week ) , ongoing alcohol use volume discontinue upon entry study . 5 . History CYC methotrexate induce pneumonitis past treatment . 6 . Hypersensitivity CYC , MPM , methotrexate . 7 . Transitional cell carcinoma bladder . 8 . Inability comply study guideline . 9 . Hemocytopenia : platelet count le 80,000/mm ( 3 ) , leukocyte count le 3,000/mm ( 3 ) , hematocrit less 20 % ( absence gastrointestinal bleeding hemolytic anemia ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2004</verification_date>
	<keyword>Relapse</keyword>
	<keyword>Immunosuppressive</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Purineantimetabolite</keyword>
	<keyword>Alternative Agents</keyword>
	<keyword>Wegener 's Granulomatosis</keyword>
	<keyword>Wegener 's Disease</keyword>
	<keyword>Blood Vessel Disorder</keyword>
	<keyword>Systemic Vasculitis</keyword>
</DOC>